COVID-19 Booster Reduced Hospitalizations, Mortality Risks
Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million UK adults who had the autumn 2022 vaccine.
Tag: Moderna vaccine COVID
All
Latest
COVID-19 Booster Reduced Hospitalizations, Mortality Risks
Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million UK adults who had the autumn 2022 vaccine.
Read More
FDA Mandates Updated Warning Labels for mRNA COVID-19 Vaccines
The FDA now requires certain COVID-19 vaccines to include safety information about the risks of myocarditis and pericarditis following administration.
Read More
Moderna Withdraws FDA Application for Combo Flu-COVID Vaccine
Moderna’s biologics license application for its flu/COVID combination vaccine candidate for adults aged 50 years and older.
Read More
FDA OKs Updated Moderna and Pfizer-BioNTech COVID-19 Vaccines
The FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
Read More
Moderna’s Bivalent Booster Candidate Shows Superior Antibody Response to Omicron
A 50 µg dose of Moderna’s bivalent booster candidate, mRNA-1273.214, demonstrated superior neutralizing antibody response against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.
Read More
FDA Approves Moderna COVID-19 Vaccine
The US FDA has approved the Moderna COVID-19 Vaccine (marketed as “Spikevax”) for the prevention of COVID-19 in individuals 18 years of age and older.
Read More
FDA Includes Myocarditis, Pericaditis Risks for Pfizer and Moderna Vaccines
The FDA has reported increased risks of myocarditis and pericarditis following vaccination with the Moderna and Pfizer-BioNTech COVID-19 vaccine.
Read More